Search

Your search keyword '"de la Varga-Martínez, Raquel"' showing total 26 results
Start Over Author "de la Varga-Martínez, Raquel"
26 results on '"de la Varga-Martínez, Raquel"'

4. VEXAS‐Syndrom erfolgreich mit Canakinumab therapiert

Author

Collantes‐Rodríguez, Cristina, primary, Jiménez‐Gallo, David, additional, de la Varga‐Martínez, Raquel, additional, Mora‐López, Francisco, additional, Garrastazul‐Sánchez, Maria Paz, additional, and Linares‐Barrios, Mario, additional

Published
2023
Full Text
View/download PDF

5. Vexas syndrome successfully treated with canakinumab

Author

Collantes‐Rodríguez, Cristina, primary, Jiménez‐Gallo, David, additional, de la Varga‐ Martínez, Raquel, additional, Mora‐López, Francisco, additional, Garrastazul‐Sánchez, Maria Paz, additional, and Linares‐Barrios, Mario, additional

Published
2023
Full Text
View/download PDF

8. Angiogenic Imbalance and Inflammatory Biomarkers in the Prediction of Hypertension as Well as Obstetric and Perinatal Complications in Women with Gestational Diabetes Mellitus

Author

Lara-Barea, Almudena, primary, Sánchez-Lechuga, Begoña, additional, Campos-Caro, Antonio, additional, Córdoba-Doña, Juan Antonio, additional, de la Varga-Martínez, Raquel, additional, Arroba, Ana I., additional, Bugatto, Fernando, additional, Aguilar-Diosdado, Manuel, additional, and López-Tinoco, Cristina, additional

Published
2022
Full Text
View/download PDF

16. Hypersensitivity to alemtuzumab. A safe and effective desensitization protocol: A case report.

Author

Gutiérrez-Fernández, Diego, Saldaña-Valderas, Mónica, de la Varga-Martínez, Raquel, Foncubierta-Fernández, Antonio, Fernández-Anguita, María J, Fernández-Valle, Maria del C, and Medina-Varo, Fermín

Subjects
ALLERGY desensitization, BASOPHILS, DRUG allergy, IMMUNOGLOBULINS, LEUKEMIA, MONOCLONAL antibodies, SKIN tests
Abstract

We describe a successful desensitization to alemtuzumab in one patient diagnosed with T-cell prolymphocytic leukaemia. Alemtuzumab treatment was initiated during infusion number 18, the patient showed cutaneous eruption with a miliary pattern, despite premedication with corticosteroids and antihistamines. The eruption returned with successive alemtuzumab infusions (infusions 19, 20 and 21), remained present for longer and was more severe with each infusion. The patient was referred to our Allergy Unit as it was necessary to maintain alemtuzumab treatment. Total immunoglobulin E level was 3 UI/ml and specific immunoglobulin E against more common pneumo-allergens, food, latex and hamster were inferior to 0.35 UI/ml. Prick test using the undiluted drug (30 mg/ml) and intradermal tests using serial dilutions (1/10, 1/100) were performed. The result of alemtuzumab skin prick test was 4 mm. The intradermal skin test result was positive at 1/100 dilution (papule: 8 mm; erythema: 12 mm). The basophil activation test with alemtuzumab was performed concluding that 10% of the basophils were activated by alemtuzumab. The patient underwent alemtuzumab desensitization according to a 12-step protocol that resolved to be safe and efficacious. Our experience may be helpful for similar clinical cases where the therapeutic options are very limited and a life-threatening condition such T-cell prolymphocytic leukaemia is present. In addition, a careful risk/benefit ratio should be considered and accurate informed consent is mandatory. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

20. Heterozygous Cylindromatosis Gene Mutation c.1628_1629delCT in a Family with Brook-Spiegler Syndrome.

Author

Arjona Aguilera, Cintia, De la Varga Martínez, Raquel, Ossorio García, Lidia, Jiménez-Gallo, David, Albarrán Planelles, Cristina, and Linares Barrios, Mario

Subjects
*GENETIC disorder diagnosis, *HEREDITARY cancer syndromes, *SKIN tumors, *ADENOID cystic carcinoma, *TUMOR suppressor genes, *GENES, *GENETIC mutation, *GENETICS, *DIAGNOSIS
Abstract

Brooke-Spiegler Syndrome (BSS) is a rare genodermatosis characterized by the progressive formation of adnexal skin tumors in the scalp and face, mainly trichoepitheliomas, cylindromas, and spiradenomas. It has also been associated with salivary glands neoplasms. It is due to mutations in the tumor suppressor gene cylindromatosis (CYLD gene) localized on chromosome 16ql2-ql3. Around 93 mutations have been described. The study of CYLD gene in patients and their relatives is of vital importance to establish the molecular diagnosis and offer appropriate genetic counseling. There is a low risk of malignancy and patients require long-term follow-up. A case of BSS in a family is described. The existence of the genetic mutation at the CYLD gene c. 1628_1629delCT in three of the women affected was demonstrated. This mutation has only been described once in a previous study. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

24. Vexas syndrome successfully treated with canakinumab.

Author

Collantes-Rodríguez C, Jiménez-Gallo D, de la Varga-Martínez R, Mora-López F, Garrastazul-Sánchez MP, and Linares-Barrios M

Subjects
Humans, Mutation, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal therapeutic use
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results